ALX4 and colorectal cancer: The ALX4 promoter was also methylated in 69.44% (75/108) of cases and none of the eight normal breast tissues [38] while in colorectal cancer patients’ serum, methylation was detected in 68% (17/25) of cases and 12% (3/25) of controls [39], a similar rate to our 50% and 11% in OC and benign cases, respectively.